The development of new therapies for the treatment of human diseases is arguably one of the most important roles of modern chemistry and biology.
In an article published in the September 18, 2014 edition of Chemistry & Biology Patrick Baeuerle and Jerry Murry shed light on a particular class of human therapies in which synthetic chemical entities are attached to expressed biologicals (proteins) with the goal to enhance clinical activity.
The scientists focus their discussion on three key categories of these derivatized biologicals: proteins conjugated with biologically inert molecules, proteins conjugated with biologically active small molecules and peptides (e.g., antibody drug conjugates or ADCs), and proteins conjugated with radio isotopes.
Overall, it is apparent by the impact on clinical activity as well as the commercial success that chemical modification of recombinant proteins is becoming of increasing importance. Therefore, Baeuerle and Murry argue that deeper understanding of the chemical reactions between large proteinaceous molecules and small molecule reagents is will allow for a more precise and elegant solutions to existing limitations in this field.
Published in: Chemistry & Biology